BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 5, 2008
View Archived Issues
Increasing Complexity in Deals Can Be a Blessing or a Curse
Read More
IDM Pops on Paper Showing Survival Benefit for Mifamurtide
Read More
Centocor's Ustekinumab Shows Good Data in Plaque Psoriasis
Read More
Financings Roundup
Read More
Clinic Roundup
Read More
Amgen Unloads 13 Molecules in $1B-plus Deal with Takeda
Amgen Inc. is selling the Japanese rights to 13 molecules, including the FDA-approved colorectal drug Vectibix (panitumumab), to Takeda Pharmaceutical Co. Ltd. in a deal potentially worth more than $1 billion. (BioWorld Today)
Read More
Amira Inks $425M FLAP Inhibitor Deal with GSK
Read More
Other News To Note
Read More